공시 • Mar 31
Chengdu Guibao Science & Technology Co.,Ltd. to Report Q1, 2026 Results on Apr 21, 2026 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report Q1, 2026 results on Apr 21, 2026 공시 • Mar 28
Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 20, 2026 Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 20, 2026, at 14:00 China Standard Time. Location: No. 16, Xinyuan Avenue, Hi-tech Zone, Chengdu, Sichuan China 공시 • Dec 31
Chengdu Guibao Science & Technology Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 28, 2026 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 28, 2026 공시 • Jul 02
Chengdu Guibao Science & Technology Co.,Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 공시 • May 09
Chengdu Guibao Science & Technology Co.,Ltd. Announces Director Appointments Chengdu Guibao Science & Technology Co.,Ltd. at its EGM held on May 7, 2025, approved: Election and nomination of non-independent and independent directors: Zhao Kexing, non-independent director; Liu Qi, non-independent director; Wang Jiayu, non-independent director; Yi Yang, independent director. 공시 • Apr 24
Chengdu Guibao Science & Technology Co.,Ltd. Approves Cash Dividend for 2024 Chengdu Guibao Science & Technology Co.,Ltd. at its Annual General Meeting held on 21 April 2025 approved cash dividend of CNY 3.00000000 per 10 shares (tax included) for 2024. 공시 • Apr 01
Chengdu Guibao Science & Technology Co.,Ltd. Announces Profit Distribution Proposal for the Year 2024 Chengdu Guibao Science & Technology Co.,Ltd. announced profit distribution proposal final Cash dividend/10 shares (tax included) is CNY 3.000000 for the year 2024. 공시 • Mar 31
Chengdu Guibao Science & Technology Co.,Ltd. to Report Q1, 2025 Results on Apr 15, 2025 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report Q1, 2025 results on Apr 15, 2025 공시 • Mar 29
Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 21, 2025 Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 21, 2025, at 14:00 China Standard Time. Location: 6F, No. 16, Xinyuan Avenue, Hi-tech Zone, Chengdu, Sichuan China 공시 • Dec 31
Chengdu Guibao Science & Technology Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 29, 2025 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 29, 2025 Reported Earnings • Oct 22
Third quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.23 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.14 (down from CN¥0.23 in 3Q 2023). Revenue: CN¥974.1m (up 36% from 3Q 2023). Net income: CN¥56.7m (down 38% from 3Q 2023). Profit margin: 5.8% (down from 13% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to CN¥14.18, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 9.7% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥24.83 per share. 공시 • Sep 30
Chengdu Guibao Science & Technology Co.,Ltd. to Report Q3, 2024 Results on Oct 22, 2024 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report Q3, 2024 results on Oct 22, 2024 Reported Earnings • Aug 24
Second quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.20 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.16 (down from CN¥0.20 in 2Q 2023). Revenue: CN¥684.0m (up 3.2% from 2Q 2023). Net income: CN¥61.6m (down 20% from 2Q 2023). Profit margin: 9.0% (down from 12% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. 공시 • Jun 29
Chengdu Guibao Science & Technology Co.,Ltd. to Report First Half, 2024 Results on Aug 24, 2024 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report first half, 2024 results on Aug 24, 2024 Declared Dividend • Apr 26
Dividend of CN¥0.30 announced Dividend of CN¥0.30 is the same as last year. Ex-date: 30th April 2024 Payment date: 30th April 2024 Dividend yield will be 2.3%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is covered by both earnings (39% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 106% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • Apr 22
Now 30% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.7% to CN¥13.06. The fair value is estimated to be CN¥18.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has grown by 6.5%. Revenue is forecast to grow by 81% in 2 years. Earnings are forecast to grow by 76% in the next 2 years. 공시 • Mar 30
Chengdu Guibao Science & Technology Co.,Ltd. to Report Q1, 2024 Results on Apr 20, 2024 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report Q1, 2024 results on Apr 20, 2024 Reported Earnings • Mar 30
Full year 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.64 in FY 2022) Full year 2023 results: EPS: CN¥0.81 (up from CN¥0.64 in FY 2022). Revenue: CN¥2.61b (down 3.3% from FY 2022). Net income: CN¥315.2m (up 26% from FY 2022). Profit margin: 12% (up from 9.3% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Chemicals industry in China. 공시 • Mar 29
Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 19, 2024 Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 19, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chengdu, Sichuan China 공시 • Feb 22
Chengdu Guibao Science & Technology to Buy Hot Melt Adhesive Firm Chengdu Guibao Science & Technology Co.,Ltd. (SZSE:300019) said it plans to buy hot melt adhesive firm with estimated valuation of CNY 480 million ($66.72 million). Reported Earnings • Feb 03
Full year 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.64 in FY 2022) Full year 2023 results: EPS: CN¥0.81 (up from CN¥0.64 in FY 2022). Revenue: CN¥2.61b (down 3.3% from FY 2022). Net income: CN¥315.2m (up 26% from FY 2022). Profit margin: 12% (up from 9.3% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥12.47, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Chemicals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥5.41 per share. 공시 • Dec 29
Chengdu Guibao Science & Technology Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 29, 2024 Reported Earnings • Oct 20
Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.16 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.23 (up from CN¥0.16 in 3Q 2022). Revenue: CN¥718.8m (up 13% from 3Q 2022). Net income: CN¥91.2m (up 45% from 3Q 2022). Profit margin: 13% (up from 9.9% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. 공시 • Sep 30
Chengdu Guibao Science & Technology Co.,Ltd. to Report Q3, 2023 Results on Oct 19, 2023 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report Q3, 2023 results on Oct 19, 2023 Reported Earnings • Aug 12
Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.20 (up from CN¥0.15 in 2Q 2022). Revenue: CN¥662.9m (down 6.9% from 2Q 2022). Net income: CN¥77.3m (up 28% from 2Q 2022). Profit margin: 12% (up from 8.4% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. 공시 • Jul 01
Chengdu Guibao Science & Technology Co.,Ltd. to Report First Half, 2023 Results on Aug 12, 2023 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report first half, 2023 results on Aug 12, 2023 Reported Earnings • Mar 26
Full year 2022 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in FY 2021) Full year 2022 results: EPS: CN¥0.64 (down from CN¥0.70 in FY 2021). Revenue: CN¥2.69b (up 5.4% from FY 2021). Net income: CN¥250.3m (down 6.5% from FY 2021). Profit margin: 9.3% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China. Board Change • Mar 14
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Xianye Tang is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
